Journal
JOURNAL OF MEMBRANE BIOLOGY
Volume 254, Issue 5-6, Pages 513-529Publisher
SPRINGER
DOI: 10.1007/s00232-021-00192-z
Keywords
SGLT inhibitor; Na/K-ATPase; ROS; Signaling
Ask authors/readers for more resources
SGLT2 inhibitors have shown significant cardiac and renal protective effects in the treatment of heart failure and kidney disease, potentially revolutionizing treatment approaches. Various theories have been proposed to explain the protective effects beyond glucose-lowering. The role of Na/K-ATPase as the primary ion transporter and its signaling function remains unexplored.
In different large-scale clinic outcome trials, sodium (Na+)/glucose co-transporter 2 (SGLT2) inhibitors showed profound cardiac- and renal-protective effects, making them revolutionary treatments for heart failure and kidney disease. Different theories are proposed according to the emerging protective effects other than the original purpose of glucose-lowering in diabetic patients. As the ATP-dependent primary ion transporter providing the Na+ gradient to drive other Na+-dependent transporters, the possible role of the sodium-potassium adenosine triphosphatase (Na/K-ATPase) as the primary ion transporter and its signaling function is not explored. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available